tiprankstipranks
Advertisement
Advertisement

OPHLF Stock Latest News

Ono’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF
Company AnnouncementsOno’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF
1d ago
OPHLF
Ono’s Phase 3 Sapablursen Trial Targets Polycythemia Vera Upside for OPHLF Investors
PremiumCompany Announcements
Ono’s Phase 3 Sapablursen Trial Targets Polycythemia Vera Upside for OPHLF Investors
13d ago
OPHLF
ONO Pharmaceutical Details FY2025 Results and FY2026 Outlook with Focus on Pipeline and Core Metrics
PremiumCompany Announcements
ONO Pharmaceutical Details FY2025 Results and FY2026 Outlook with Focus on Pipeline and Core Metrics
14d ago
Ono Pharmaceutical Delivers Strong FY 2025 Profits but Guides for Lower Revenue in FY 2026
PremiumCompany Announcements
Ono Pharmaceutical Delivers Strong FY 2025 Profits but Guides for Lower Revenue in FY 2026
14d ago
Is OPHLF a Buy, Before Earnings?
PremiumPre-Earnings
Is OPHLF a Buy, Before Earnings?
15d ago
ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso
PremiumCompany AnnouncementsONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso
2M ago
OPHLF
ONO Pharmaceutical Posts Strong Profit Growth in Q3 FY2025 and Maintains Full-Year Outlook
Premium
Company Announcements
ONO Pharmaceutical Posts Strong Profit Growth in Q3 FY2025 and Maintains Full-Year Outlook
4M ago
OPHLF Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
OPHLF Earnings this Week: How Will it Perform?
4M ago
ONO Pharmaceutical Reports Strong Q2 Financial Performance with Revenue Growth
PremiumCompany Announcements
ONO Pharmaceutical Reports Strong Q2 Financial Performance with Revenue Growth
7M ago
Ono Pharmaceutical’s Tirabrutinib Study: Key Insights for Investors
PremiumCompany Announcements
Ono Pharmaceutical’s Tirabrutinib Study: Key Insights for Investors
7M ago
OPHLF
Ono Pharmaceutical’s Phase 3 Trial: A New Hope for PCNSL Treatment
PremiumCompany Announcements
Ono Pharmaceutical’s Phase 3 Trial: A New Hope for PCNSL Treatment
7M ago
OPHLF
Ono Pharmaceutical’s ONO-1110: A Promising Study for Interstitial Cystitis
PremiumCompany Announcements
Ono Pharmaceutical’s ONO-1110: A Promising Study for Interstitial Cystitis
7M ago
OPHLF
ONO Pharmaceutical Advances Fibromyalgia Treatment with ONO-1110 Study
PremiumCompany AnnouncementsONO Pharmaceutical Advances Fibromyalgia Treatment with ONO-1110 Study
7M ago
OPHLF
Ono Pharmaceutical’s ONO-4538 Study: A Potential Game-Changer for Richter’s Transformation
Premium
Company Announcements
Ono Pharmaceutical’s ONO-4538 Study: A Potential Game-Changer for Richter’s Transformation
7M ago
OPHLF
Bristol-Myers Squibb and ONO Pharmaceutical’s New Study on Nivolumab for NSCLC: What Investors Need to Know
Premium
Company Announcements
Bristol-Myers Squibb and ONO Pharmaceutical’s New Study on Nivolumab for NSCLC: What Investors Need to Know
7M ago
BMY
ONO Pharmaceutical’s BRILLIANT Study: A Potential Breakthrough for Steroid-resistant Pemphigus
PremiumCompany Announcements
ONO Pharmaceutical’s BRILLIANT Study: A Potential Breakthrough for Steroid-resistant Pemphigus
7M ago
OPHLF
Ono Pharmaceutical’s ONO-1110: A Promising Treatment for Postherpetic Neuralgia
PremiumCompany Announcements
Ono Pharmaceutical’s ONO-1110: A Promising Treatment for Postherpetic Neuralgia
7M ago
OPHLF
ONO Pharmaceutical’s ONO-2020: A Promising Alzheimer’s Study Update
PremiumCompany Announcements
ONO Pharmaceutical’s ONO-2020: A Promising Alzheimer’s Study Update
7M ago
OPHLF
ONO Pharmaceutical’s Phase III Study on Cenobamate: A Potential Game-Changer for Epilepsy Treatment
PremiumCompany Announcements
ONO Pharmaceutical’s Phase III Study on Cenobamate: A Potential Game-Changer for Epilepsy Treatment
7M ago
OPHLF
Ono Pharmaceutical’s ONO-4538 Study: A Closer Look at Its Market Potential
PremiumCompany AnnouncementsOno Pharmaceutical’s ONO-4538 Study: A Closer Look at Its Market Potential
7M ago
OPHLF
ONO Pharmaceutical’s ONO-2020: A Promising Study in Alzheimer’s Agitation
Premium
Company Announcements
ONO Pharmaceutical’s ONO-2020: A Promising Study in Alzheimer’s Agitation
7M ago
OPHLF
Ono Pharmaceutical’s Cenobamate Study: A Potential Game-Changer for Epilepsy Treatment
Premium
Company Announcements
Ono Pharmaceutical’s Cenobamate Study: A Potential Game-Changer for Epilepsy Treatment
7M ago
OPHLF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >